Table 1 |
||
|
Cohort characteristics |
||
|
n |
% |
|
|
|
||
|
Total cohort (n = 233) |
||
|
|
||
|
Age |
||
|
Mean/median age |
23-85 y |
|
|
Range |
49/47 y |
|
|
|
||
|
Tumor stage (FIGO |
||
|
Ia |
4 |
(1.7) |
|
Ib |
139 |
(59.7) |
|
IIa |
17 |
(7.3) |
|
IIb |
48 |
(20.6) |
|
IIIb |
1 |
(0.4) |
|
IVa |
7 |
(3.0) |
|
IVb |
17 |
(7.4) |
|
|
||
|
Postoperative residual tumor |
||
|
R0 |
212 |
(91.0) |
|
R1 |
21 |
(9.0) |
|
|
||
|
Subcohort with follow-up informations (n = 178) |
||
|
|
||
|
Applied therapy regimen |
||
|
Observation |
86 |
(48.3) |
|
Adjuvant radiotherapy alone |
42 |
(23.6) |
|
Adjuvant chemoradiotherapy |
50 |
(28.0) |
|
|
||
|
Clinical follow-up |
||
|
Median follow-up time: 49 months |
||
|
Recurrence |
47 |
(25.4) |
|
Dead of disease (DOD) |
41 |
(22.2) |
|
|
||
|
Ihnen et al. BMC Cancer 2012 12:140 doi:10.1186/1471-2407-12-140 |
||
